Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing genotypes and high metastases rates.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Phase IIb trial in osteosarcoma completed. FDA Rare Pediatric Disease and Fast Track designated. BLA activities in progress.
OST-tADC
Preclinical · ActiveModality: tunable drug conjugate
Aliases OST-tADC-A (Exatecan-silanol-FRa)
Target Folate receptor alpha (FRa)
Partnerships BlinkBio (in-licensed tunable drug conjugate technology)
Indications
Ovarian cancer and other folate receptor alpha-overexpressing tumors(Preclinical)
Status note Tunable drug conjugate platform (ligand, payload, linkers). Lead program OST-tADC-A (Exatecan-silanol-FRa) planned for IND to initiate a Phase 1 trial in ovarian cancer and other folate receptor alpha-overexpressing tumors including endometrial cancer and certain osteosarcomas, pending preclinical and GLP toxicology completion.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.